• Neurocrine Biosciences director Kevin Charles Gorman sold 245,088 common shares on May 19, 2026 at an average price of $154.33.
• He exercised non-qualified stock options for 205,088 shares the same day at $43.24.
• His direct holdings stood at 511,293 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001201096-26-000010), on May 21, 2026, and is solely responsible for the information contained therein.